Telomerase activity in tumours is often associated with p53 mutation. Many antitelomerase therapies take advantage of the inability of cells expressing mutant p53 to undergo replicative senescence, since this allows telomere erosion to continue until 'crisis', hence providing the desired cytotoxic effect. However, some tumour types, including breast, melanomas and thyroid, retain wild-type p53 function and the effectiveness of antitelomerase therapies in such tumour cells have not been adequately addressed. To explore this, we made use of two thyroid cancer cell lines K1 and K2, which retain wt p53. Telomere erosion induced by the expression of a dominant-negative (DN) hTERT resulted in delayed onset of growth arrest in K1 and K2 cells, reminiscent of replicative senescence, with low levels of BrdU labelling and apoptosis, associated with high p21 WAF1 and senescence-associated b galactosidase expression. In contrast, abrogation of p53 function by the expression of HPV16 E6 in K1 and K2 cells either at the same time as DNhTERT or just prior to the onset of senescence allowed cells to continue growing until 'crisis'. Likewise, microinjection of a p53 neutralizing antibody into 'senescent' K1 DNhTERT cells permitted re-entry into the cell cycle. We conclude that thyroid tumour cells with wild-type p53 retain an intact p53-mediated growth arrest response to telomere erosion. This raises the intriguing question of why, therefore, p53 mutation is not selected for in such cancers, and also calls into question the therapeutic value of telomerase inhibitors in such cases.
Introduction
The p53 tumour suppressor gene product is central to the cellular response to stress, signalling cell cycle arrest in response to numerous stimuli, including DNA damage, mitotic spindle dysfunction, hypoxia (Balint and Vousden, 2001 ) and telomere erosion (WynfordThomas, 1997) . Many of these conditions arise in human tumours, and indeed telomere erosion probably occurs in the majority, at least in their early stages (Granger et al., 2002) .
The activation of the p53 signalling pathway by one or more of these stimuli clearly becomes self-limiting at some point in the development of most cancers, since inactivation of p53 by direct mutation, or equivalent indirect mechanisms (such as mdm-2 amplification), occurs in the great majority of advanced human cancers (Soussi, 2000) . Nevertheless, a significant minority of tumour types, including some breast (Wynford-Thomas and Blaydes, 1998; Pharoah et al., 1999) and most melanomas (Florenes et al., 1994; Lubbe et al., 1994) , retain wild-type p53 protein, without any obvious mechanism for functional inactivation. The finding that wild-type (wt) p53 appears to be tolerated in many cancers, coupled with the expectation that therapeutic activation of p53-dependent apoptosis should be easier in the absence of mutation, has heightened interest in defining the functional status of p53 in such tumours (Hudson et al., 1999; Crook et al., 2000) .
A particularly well-characterized example is provided by tumours of the thyroid follicular epithelium, in which over 95% of cancers (excluding the very rare anaplastic form) retain wt p53 (Wynford- Thomas, 1997) . Furthermore, functional studies using exogenous DNA-damaging agents have suggested that in these tumour cells the p53-mediated growth arrest pathway is intact, at least in response to 'gross' genomic damage .
To attempt to explain why thyroid cancers apparently do not require p53 mutation at any stage in their development, we have investigated here the possibility that a more subtle defect in the p53 pathway exists in these tumours, preventing activation of p53-mediated cell cycle arrest in response specifically to telomere erosion. This, in untreated tumours, is likely to represent a more relevant source of p53-activating signals than gross genomic DNA damage. To test this hypothesis, telomere erosion was imposed on thyroid tumour cell lines, via the introduction of a dominant-negative (DN) mutation of hTERT (Hahn et al., 1999) , the catalytic subunit of telomerase. Using this approach also allowed the question of the therapeutic efficacy of telomerase inhibitors in tumours retaining wt p53 function to be addressed.
Here we report that thyroid cancer cell lines with wildtype p53 are able to mount a p53-dependent response to telomere erosion. The senescent-like state of growth arrest (i.e. not cell death) induced in these lines has important implications for antitelomerase-based therapies.
Results
K1 cells are an example of a well-differentiated papillary thyroid cancer cell line. Extensive characterization of this line demonstrated that the CDKN2 gene locus was deleted (Jones et al., 1996) , B-RAF was mutated (Soares et al., 2003) , the cells were telomerase positive and immortal (Jones et al., 1998) and retained normal p53 sequences . A series of K1 derivatives were created, including a line with abrogated p53 following infection with HPV16 E6 (K1E6) and K1 neo as a control . Our previous finding of a G1/S checkpoint in K1 neo, but not K1E6, after bleomycin treatment established that at least under extreme (nonphysiological) stimuli these cells retained p53 function.
Expression of DNhTERT abolishes telomerase activity in K1 thyroid cancer cells
A retrovirus expressing a DN version of the catalytic subunit of telomerase was created by introduction of pBABE DNhTERT puro (Hahn et al., 1999) into an amphotrophic producer cell line. K1 neo and K1E6 cells were infected with either DNhTERT puro or pBABE puro (control) retroviruses and plated at densities sufficient to produce individual colonies after selection in puromycin. Prior to infection, analysis of both K1 neo and K1E6 cells indicated that there should be enough telomere length to allow a prolonged period of growth before a proliferative lifespan barrier was reached (data not shown). Clones were isolated and expanded as separate cell lines from which S100 cell extracts were prepared for analysis in TRAP assays. Expression of DNhTERT in both K1 neo and K1E6 abolished telomerase activity, as indicated by the lack of the six base pair DNA ladder that was present in extracts of K1 neo/puro, K1E6 puro and a control HEK293 cell line (Figure 1 ).
Abolition of telomerase activity in K1 cells causes telomere erosion
Three subclones were chosen from both K1 neo and K1E6 after DNhTERT infection and routinely subcultured. These were sampled regularly to ascertain the maintenance of telomerase repression, and DNA was extracted for telomere length analysis. Reactivation of telomerase is an event that confers an overwhelming growth advantage on these cultures and is a commonly reported drawback of telomerase inhibitors (Delhommeau et al., 2002) . Unfortunately, two of the K1 neo DNhTERT clones were shown to be telomerase positive after a prolonged period of culture (data not shown). However, the remaining subclone remained telomerase negative for the duration of the study and was used for the analyses described below.
Telomere length was analysed in K1 neo and K1E6, DNhTERT and pBABE puro, subclones using the terminal restriction fragment (TRF) assay (Jones et al., 1998) (Figure 2) . The assay detects all telomeric sequences that are displayed as smears, reflecting differences in telomere length between both individual chromosomes and cells within the population. No telomere erosion was seen in two control K1 neo/puro subclones analysed at 21 or 159 pd, and 20 or 160 pd after infection, respectively (Figure 2a ). In the K1 neo subclone expressing DNhTERT, telomere erosion was detected, as shown by the progressive appearance of lower molecular weight TRFs with increasing replicative lifespan (Figure 2a) . Likewise, no telomere erosion was seen in two control K1E6 puro subclones analysed at 24 or 114 pd, and 23 or 110 pd after infection (Figure 2b ). (The differences in initial TRFs between the two clones are a reflection of telomere length variation in the K1E6 population from which they were selected.) In contrast, K1E6 subclones expressing DNhTERT showed obvious telomere erosion over the lifespan of the culture (Figure 2b ). Expression of DNhTERT abolishes telomerase activity in thyroid cancer cells. K1 neo or K1E6 thyroid cancer cells were infected with retroviruses expressing either DNhTERT or a puro vector control. Cell extracts prepared from representative subclones were assayed for telomerase activity using the TRAP assay (1000 cell equivalents per reaction). When extracts are pretreated at 851C for 10 min, telomerase activity is abolished ( þ heat). Lanes 1 and 2, 293 positive control; lanes 3 and 4, K1 neo puro; lanes 5 and 6, K1 neo DNhTERT; lanes 7 and 8, K1E6 puro; lanes 9 and 10, K1E6 DNhTERT; lane 11 (B) is a buffer reagent blank used to detect potential PCR contamination. All samples successfully amplified a control substrate (ITAS; *) Figure 3a) . The three K1E6 DNhTERT subclones stopped growing between 49 and 83 pd postinfection (Figure 3b ).
Major differences in the phenotypes of the subclones were observed as they approached the end of their growth, depending on the functional status of p53. The K1 neo DNhTERT-expressing clone proliferated rapidly for over 80 pd after which the doubling time began to increase accompanied by the accumulation of large, flattened cells with granular nuclei, reminiscent of the Figure 2 Expression of DNhTERT induces telomere erosion in thyroid cancer cells. TRF analysis of K1 neo and K1E6 cancer cells expressing DNhTERT. Genomic DNA was digested, separated and probed in situ with a telomere repeat specific probe. (a) Expression of puro vector control (lanes 1-4) or DNhTERT (lanes 6-15) in K1 neo. Lanes 1 and 2, pBABE puro control clone 5 at 21 and 159 pd after infection; lanes 3 and 4, pBABE puro control clone 9 at 20 and 160 pd after infection; lane 5, lHindIII ladder; lanes 6-15 K1 neo DNhTERT clone 14 at 22, 33, 51, 65.5, 71, 75, 80, 81.5, 87 .5, 90 pd after infection. (b) Expression of puro vector control (lanes 1-4) or DNhTERT (lanes 5-11) in K1E6. Lanes 1 and 2, pBABE puro control clone 1 at 23.5 and 114 pd after infection; lanes 3 and 4 pBABE puro control clone 11 at 22.5 and 110 pd after infection; lanes 6-11 K1E6 DNhTERT clone 1 24, 37, 47.5, 55.5, 69, 75.5, 82.5 pd after infection; lane 12, lHindIII ladder In sharp contrast to the senescent behaviour of K1 neo DNhTERT, the end of the replicative lifespan of K1E6 DNhTERT-expressing clones was reminiscent of an M2 crisis-like state ( Figure 4s Telomerase inhibition induces a senescent-like state in K2, another thyroid cancer cell line retaining wild-type p53
In order to show that the arrest induced by telomerase inhibition in K1 cells was not peculiar to a single cell line, DNhTERT was also introduced into K2, another similar thyroid cancer cell line with wild-type p53. After infection, 20 puro-resistant colonies were detected by immunocytochemistry (positivity indicated by brown peroxidase reaction product); BrdU: incorporation of bromodeoxy uridine; SAb Gal: senescence-associated marker assessed by X-Gal histochemistry (blue reaction product). Nuclei are lightly counterstained with haematoxylin to aid visualization. DAPI: counterstain to detect nuclei in FITC stained cells in TUNEL assay
Telomerase inhibition in cancer cells with wild-type p53 A Preto et al isolated and expanded. These were then analysed for telomerase activity and telomere length as before (data not shown). Three clones were chosen for further analysis based on the absence of telomerase activity ( Figure 5a ) and relatively short terminal restriction length fragments in order to bring the experiment to an earlier conclusion. As with K1, the replicative lifespan of all three K2 DNhTERT clones was terminated by entry into a state of senescent-like growth arrest associated with telomere erosion (Figure 5b ), while the division rate of K2 puromycin controls was unaffected (Figure 5c ). Phenotypically, growth-arrested K2 DNhTERT cells were similar to K1 DNhTERT cells at the same stage ( Figure  5d Telomere-dependent, senescence-like state of growth arrest in cancer cells requires wt p53 function Growth to crisis rather than senescence in the presence of both DNhTERT and E6 strongly suggests that the senescent-like state induced requires, and is dependent on, wild-type p53 function. However, the occurrence of additional unknown genetic or epigenetic changes during the long-term culture of these cells, which may be necessary for escape from senescence, cannot be formally excluded. To address this, two additional complementary approaches were used to demonstrate the effect of abrogating p53 function just prior to cells entering the senescent-like state, namely expression of HPV16 E6 and microinjection of neutralizing anti-p53 antibodies.
Since K2 cells (as opposed to K1) expressing DNhTERT carried only the puromycin resistance gene, this allowed the use of a retrovirus expressing HPV16 E6 and neo R to abrogate p53 function. HPV16 E6 or pBABE neo was therefore introduced into a K2 clone expressing DNhTERT, 10 pd prior to the onset of the senescent-like state. Observation of the cells 2 weeks Since the use of the HPV16 E6 retroviral vector was precluded in K1 DNhTERT as the cells were already G418 resistant, microinjection of DO-1, an antibody that inactivates the p53 protein by binding to its Nterminal transactivation domain, was used as an alternative approach, which also avoids any potential confounding additional actions of E6. Previously, we had shown that nuclear injection of DO-1 into senescent HDFs allowed the cells to re-enter the cell cycle (Gire and Wynford-Thomas, 1998; Davis et al., 2003) . Senescent-like K1 neo DNhTERT cells microinjected either with IgG ( Figure 7b ) or with DO-1 (Figure 7e ) were identified by Texas Red staining. Unexpected problems were encountered using senescent K1 neo DNhTERT, which had been growth arrested for prolonged periods since, although viable prior to intervention, these cells responded to microinjection by dying, irrespective of whether control or DO-1 antibodies were injected (data not shown). In order to avoid this nonspecific effect, it was necessary to inject cells in a culture that was not fully senescent. In cells that were injected with DO-1, there was a marked increase in cells showing BrdU labelling (33.1%74.1; Figure 7f ) compared to those that received IgG alone (16.2%73.6; Figure 7c ). Therefore, neutralization of p53 in these cells overcame the senescent-like state, further emphasizing its dependence on the function of the wt protein. Figure 6 Abrogation of p53 prior to induction of a senescent-like state in K2 cancer cells allows bypass of senescence. K2 cells transduced with DNhTERT were further infected, prior to senescence, with retroviruses expressing either HPV 16 E6 neo or neo alone. Cells were photographed 14 days after infection and selection (a,e; cycling) and 14 days later at the end of their lifespan (crisis; b or senescent; f). TUNEL assays were performed at these end points (c, d, g and h) To provide evidence for activation of the p53 pathway in 'senescent' cells expressing DNhTERT, Ser 15 phosphorylation and the downstream effector p21 WAF1 were analysed by Western blotting. Cell extracts were prepared from senescent-like K1 neo and K2 cells expressing DNhTERT and age-matched pBABE puro controls. Phosphorylated p53 Ser 15 bands of increased intensity were detected in both senescent K1 neo and K2 compared to lower levels in the controls (Figure 8a,b) . The levels of p21 were also increased in cells in the arrested state (Figure 8c,d) , confirming the immunohistochemical data (Figures 4h and 5k ) that p53 was transcriptionally active in response to telomere erosion.
For comparison, we also determined Ser 15 p53 phosphorylation in K1 neo, K2 and a series of control cell lines after UV and ionizing radiation, which is known to increase in response to these agents. Ser 15 phosphorylation was low or undetectable in the absence of DNA damage, but increased many fold after both UV and ionizing radiation (Figure 8e-i) and in the latter without any increase in total p53 protein (as shown by DO-1 (Figure 8j-n) . The greatly increased fold change in Ser 15 phosphorylation after exogenous DNA damage, compared to that induced by telomere erosion, reflects the differences in the intensity of the stimuli provided.
Discussion
Wild-type p53 protein in cancer cell lines can be activated by a 'biologically relevant' stress signal Using two well-characterized wt p53 cell lines phenotypically and genetically representative of the most common form of thyroid cancer (papillary carcinoma), we have shown here that progressive telomere erosion following experimental inhibition of telomerase activity results in the delayed onset of a senescent-like state characterized by cell cycle arrest, a very low cell death rate and elevated levels of p21
WAF1
, associated with increased phosphorylation of p53 protein at serine 15, a known site for post-translational activation (Webley et al., 2000) . Furthermore, abrogation of p53 function through the expression of HPVE6 conferred escape from this state, allowing cells to continue to grow until they reached a crisis-like end point with a high cell death rate, consistent with critical loss of telomere function. We conclude, therefore, contrary to our original hypothesis of a more subtle defect in the p53 pathway in these tumours, preventing activation of p53-mediated cell cycle arrest, that telomere erosion can indeed activate a p53-dependent proliferative lifespan barrier in these thyroid cancer cell lines, and by inference in the papillary cancers from which they were derived.
Precocious activation of telomerase in thyroid cancers may explain their tolerance of wild-type p53 function
Previous studies by others and ourselves have shown that between one to two-thirds of thyroid cancers are apparently telomerase-negative and that many of these have clearly undergone telomere erosion in vivo (Brousset et al., 1997; Matthews et al., 2001) . Given that p53-mediated growth arrest can still be triggered by telomere erosion, this raises the intriguing question as to how these cancers are able to continue to develop despite the functional p53, and why p53 mutation is not eventually selected for.
The simplest explanation for the apparently telomerase-negative cases is that by the time of clinical presentation, telomere erosion has simply not yet reached the point at which p53 activation is triggered. For the telomerase-positive cases (up to two-thirds in some series), however, one has to postulate that activation or upregulation of telomerase (hTERT expression) must have occurred before telomere erosion had reached the p53-activating threshold. Why such 'precocious' telomerase activation should be seen in thyroid, but not in most other cancer types, however, remains unknown. There is no reason to believe that Figure 8 P53 phosphorylation status in cancer cell lines retaining wild-type p53 in response to telomere erosion and DNA damage. Protein extracts were prepared from K1 neo DNhTERT and K2 DNhTERT clones at senescence and pBABE puro controls. Extracts (30 mg) were separated, transferred to PVDF membranes and probed with (a) anti-p53 Ser 15 or (c) anti-p21 WAF1 antibodies. Equal gel loading was confirmed by India ink staining of membranes (b,d) . Protein extracts were also prepared from a series of normal and cancer cell lines after UV irradiation (UV), ionizing radiation (IR) or mock treatment (À), and probed with anti-p53 Ser 15 (e-i) or DO-1 (j-n) antibodies. Cell lines: HCA2 (e,j), HCA2 hTERT (f,k), normal thyrocytes (g,l), K1 (h,m), K2 (i,n) hTERT expression is less tightly repressed in normal thyroid cells than in other cell types. We do, though, have preliminary evidence from another in vitro model (Bond et al., 1996) that thyroid cells in which both p53 and Rb function have been abrogated by the expression of SV40T enter a senescent-like state from which they can escape by activation of telomerase, hence implying the existence of a p53-independent proliferative lifespan barrier triggered by telomere erosion. If the frequency of mutations affecting this (unknown) pathway were sufficiently low such that in practice de-repression of hTERT expression was the most likely mechanism of escape, this could explain the frequent finding of telomerase-positive, but p53 wild type, thyroid cancers. In other words, in these tumours, the need for p53 mutation has effectively been pre-empted by telomerase activation occurring prior to the stage at which the p53 pathway becomes rate limiting.
Implications for use of antitelomerase therapies in tumours retaining wild-type p53 function
Aside from these implications for thyroid tumour biology, the data presented here have a more general significance in relation to novel therapies targeting telomerase. Numerous proof-of-principle studies have demonstrated the ability of a wide range of telomerase inhibitors (targeting the RNA or catalytic component) to bring about delayed death of human cancer cells in vitro, raising obvious hopes for their potential in cancer treatment (Goldman, 2003; Saretzki, 2003) . However, this work has made use of arbitrarily selected cancer cell lines, nearly all of which had p53 mutations, and therefore not surprisingly showed end points consistent with the crisis-like state observed here in the thyroid cancer cells expressing HPVE6. Our results raise the important caveat that cancer cells that have retained functional wild-type p53 will probably have a very different response to telomerase inhibitor therapy, namely an end point of viable growth arrest rather than cell death. Clearly, this would make such therapies a very much less attractive option, since the maintenance of such a 'cytostatic' response would probably entail continuous long-term treatment, raising of course the likelihood that resistant subclones will emerge. (Targeting of the proposed telomere 'capping' function of telomerase (Saretzki, 2003) may also lead only to a reversible 'senescence' rather than apoptosis in such cells.)
While these considerations are unlikely to be clinically significant in relation to thyroid cancer, for which conventional therapies are usually effective, they are potentially of major significance for more aggressive wild-type p53 cancers, in particular melanoma. In addition in some solid tumour types with wild-type p53 (e.g. colon and ovary), the tumours themselves appear to be somewhat more sensitive to conventional agents, but the overall cure rate is woefully inadequate. We would argue therefore that p53 status, and the distinction between senescence and crisis as therapeutic end points, have significant implications and should be important factors in the design of future clinical trials of telomerase inhibitors.
Materials and methods

Cell strains and culture
Primary monolayer cultures of follicular epithelial cells (99% epithelial as judged by cytokeratin immunostaining) were prepared from surgical samples of normal thyroid tissue by protease digestion and mechanical disaggregation. A431, primary thyrocytes and K1 neo, K1E6, K2 human thyroid cancer cell lines and their derivatives were grown in monolayers in a 2 : 1 : 1 mixture of Dulbecco's modified Eagle's medium (DMEM), Ham's F-12 medium and MCDB104 (all from Life Technologies, Paisley, UK). HCA2 human diploid fibroblasts, OE and cCRIP, were grown in DMEM and 293 cells in EMEM. All media were supplemented with 10% foetal calf serum, except for OE and cCRIP for which calf serum was used (both supplied by Imperial Laboratories, London, UK).
Retroviral gene transfer
Genes were transduced into thyroid cancer cell lines using amphotropic retroviral vectors. For all infections, 2 Â 10 5 cells were plated in 60 mm dishes, and 2 days later exposed to retrovirus-containing medium from near-confluent producer cells, containing 8 mg/ml polybrene. At 2 days after infection, cells were serially diluted and replated at densities appropriate to produce either polyclonal or monoclonal populations. For drug selection, G418 was used at a concentration of 400 mg/ml and puromycin at 2.5 mg/ml. A retrovirus expressing human papilloma virus type 16 E6 protein (HPV 16 E6 neo) (Shay et al., 1993) conferring resistance to G418 was used as previously described (Bond et al., 1999) . The dominantnegative D710A V711I mutant of hTERT was a gift from W Hahn and R Weinberg and supplied in the vector pBABE puro. Ecotropic DNhTERT puro retroviruses were produced by plasmid transfection of a producer cell line, OE, followed by selection in puromycin. Amphotropic producer cells (cCRIP) were in turn infected with ecotropic supernatants, and isolated subclones were titred on A431 cells.
Detection of SA b-gal activity
At 2 days after plating on coverslips, endogenous senescenceassociated b-galactosidase activity (Dimri et al., 1995) was assessed histochemically using X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) as a substrate.
Assessment of DNA synthesis by BrdU incorporation
Cells were labelled by incubation in 50 mM bromodeoxyuridine (BrdU) for 1 h, following which nuclear incorporation was detected by immunoperoxidase immunocytochemistry, as previously described (Bond et al., 1999) .
Immunocytochemistry
For p21
WAF1 detection cells were plated onto coverslips 2 days prior to analysis, fixed in 4% paraformaldehyde (10 min) and then pretreated with 50 mM glycine (10 min), 0.2% Triton X-100 (10 min) and 0.3% H 2 O 2 (3 min). Nonspecific binding was blocked with 2% horse serum (30 min). Anti-p21 WAF1 antibodies (Clone 6B6; Cambridge Bioscience, UK) (Bond et al., 1999) were applied followed by a mouse-specific avidin-biotinperoxidase (ABC) system (Novocastra). Sites of antibody binding were visualized by the deposition of brown polymer following incubation in diaminobenzidine-hydrogen peroxide solution. Labelling indices were determined from a count of at least 500 cells per datum point and expressed as a mean percentage7the standard error.
Detection of apoptotic cells
Cytospin preparations of both floating and attached cells were harvested from each sample and adhered to glass slides using a cytospin apparatus. After fixation with 4% paraformaldehyde (30 min) at room temperature, cells were washed in PBS and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate (2 min) on ice. TDT-mediated dUTP Nick End Labelling (TUNEL) analysis using an in situ death detection kit fluorescein (Roche) was performed according to the manufacturer's instructions.
Microinjection of antip53 antibodies
Senescent HCA2 and K1 cells were microinjected using an Eppendorf system as described previously (Gire and WynfordThomas, 1998) . Mouse monoclonal antibody DO-1 (isotype IgG2ak) or control mouse IgG (Sigma) was injected at a concentration of 2 mg/ml in PBS, together with rabbit IgG (12 mg/ml). Following injection, cells were incubated in fresh medium for 48 h followed by 20 mM BrdU for 4 h. BrdU incorporation was detected in fixed cells by incubation in a 1 : 100 dilution of anti-BrdU (isotype IgG1k; Dako) with DNAse I (25 U/ml) for 2 h at 371C, followed by incubation for 1 h at room temperature in a 1 : 50 dilution of FITC conjugated goat anti-mouse-IgG1-isotype specific antibodies (Southern Biotechnology Associates to avoid a cross-reaction with injected DO-1). Microinjected cells were detected using a 1 : 800 dilution of goat anti-rabbit-Texas red conjugate (Southern Biotechnology Associates). Nuclei were visualized by staining with 0.5 mg/ml 4 0 -6-diamidino-2-phenylindole (DAPI).
Telomerase and telomere length assays
Telomeric repeat amplification protocol (TRAP) assays and TRF length measurements were performed as previously described (Jones et al., 1998) . For TRAP assays, protein extracts were prepared from trypsinized cells and diluted to 1000 cell equivalents per reaction, where an oligonucleotide substrate was extended by telomerase, amplified by PCR and products separated on 10% polyacrylamide gels. Products were visualized by Sybr Gold staining and detected by fluorimaging (Storm, Amersham Biosciences). For TRF analyses, 1 mg of genomic DNA extracted using a Nucleon kit (Amersham) was digested with Hinf I and Rsa I, separated on 0.5% agarose gels and the dried gels probed with 5 0 -CCCTAACCCTAACCCTAA-3 0 end-labelled with g 32 P-ATP. TRFs were detected by phosphorimaging.
DNA-damaging agents
For UV irradiation of cells, medium was removed and they were exposed to 25 J/m 2 of UVC (254 nm, UVG-11 Mineralight lamp UV Products, San Gabriel, CA, USA). Cells were left to recover for 16 h prior to harvesting. For g-irradiation (IR), sealed flasks were exposed to a total dose of 5 Gy from a 137 Cs source for and incubated for 4 h before harvesting.
Immunoblotting
Cells were lysed for 5 min at 41C in a 50 mM Tris buffer, pH 8.0, containing 1% NP40, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 2 mM sodium metavanadate, 3 mM phenylmethylsulphonyl fluoride and aprotinin and leupeptin at 10 mg/ml. Protein samples (30 mg each) were separated on 10% SDS-PAGE gels and transferred onto PVDF (Millipore). Primary antibodies raised against p21 WAF1 (clone 6B6; Cambridge Bioscience) (Bond et al., 1995) , p53 (DO-1 (Vojtesek et al., 1992) (Oncogene Science AB-6) and an N-terminal epitope containing phosphorylated Ser 15 (Cell Signalling Technology, rabbit polyclonal, 9284) were used. Antibody binding was detected by goat anti-mouse peroxidase conjugate and visualized by the enhanced chemiluminescence detection system (Amersham Biosciences). The filter was subsequently stained with India ink and loaded protein was quantified by using a Bio-Rad imaging densitometer with Molecular Analyst software. All immunoblots were performed with at least three independent cell extracts.
